Amgen's Phase 3 erenumab clinical trial has turned in positive results.
The study, known as ARISE, was designed to assess the safety and effectiveness of ernumab for the prevention of migraine headaches.
The data produced by the ARISE trial showed that the study was successful in meeting its primary goal. This was to demonstrate that erenumab drastic reduction in the number of days in which patients suffered migraines during a month. This was compared to placebo over a 12-week period.
"People with episodic migraine lose a substantial part of their lives to migraine, and many face intolerable pain and physical impairment, frequently accompanied by a significant disruption of their daily activities. Unfortunately, there are limited preventive treatment options currently available for these patients," Amgen Executive Vice President of Research and Development Dr. Sean Harper said. "These positive results, along with the recent chronic migraine results, contribute to the growing body of evidence supporting erenumab as an innovative treatment option for people who are suffering from this debilitating disease."
There were 577 patients enrolled in the randomized, double-blind, placebo-controlled trial who received either a 70 mg. dose of erenumab or placebo.